Clinical Data Enters Key Collaboration with the Sudden Arrhythmia Death Syndromes (SADS) Foundation.

Clinical Data to be Lead Sponsor and Will Work with the SADS Foundation on Building Awareness for Heart Rhythm Abnormalities with Payers, Providers and Patients

NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ: CLDA) today announced that its PGxHealth division has entered a partnership with the Sudden Arrhythmia Death Syndromes (SADS) Foundation to be a primary sponsor of the organization. As part of the agreement, Clinical Data will serve as a Summit Sponsor for the 2007 Climb to Conquer SADS, which will take place June 23-25, 2007 on Mt. Rainier. PGxHealth will support a team from the SADS Foundation that will attempt to climb Mt. Rainier to raise money and awareness for sudden arrhythmia death syndromes like the congenital long QT syndrome (LQTS).

The Climb to Conquer SADS sponsorship marks the beginning of what PGxHealth and the SADS Foundation expect to be an ongoing relationship between the two organizations to support families who are genetically predisposed to sudden death due to heart rhythm abnormalities. PGxHealth and the SADS Foundation will work together to increase public knowledge of the warning signs of heart rhythm abnormalities that could portend sudden cardiac death and the public's understanding of the importance of genetic testing for the diagnosis and treatment of these conditions. The two groups will also form a task force to actively engage payers regarding the reimbursement for these critical genetic tests.

"Sudden arrhythmia death is a particularly tragic occurrence in part because, with today's diagnostic tools and treatments, heart rhythm abnormalities are a manageable health condition. Clinical Data's partnership with the SADS Foundation will assist physicians and patients in gaining access to state of the art technologies in this area and will educate these and other constituents, including payers, on the value of genetic testing," said Drew Fromkin, Chief Executive Officer of Clinical Data. "It is an honor to work with the dedicated individuals at the SADS Foundation and to support awareness of heart rhythm abnormalities and the role genetic testing can play in saving lives."

"Sudden arrhythmia death syndromes continue to kill otherwise healthy infants, children, adolescents, and adults at an unacceptably high rate. Fortunately, death can be avoided if these heart rhythm abnormalities are caught early and treated," said SADS Foundation president Michael J. Ackerman, MD, PhD. "For this reason we are very excited to enter into this agreement with Clinical Data. The company's FAMILION([R]) test is a vital tool for diagnosing these potentially lethal syndromes. Our collective efforts to generate awareness for tests such as FAMILION and other early detection tools will save lives by reducing the frequency of sudden arrhythmia death."

For more information about the FAMILION test, visit: http://www.pgxhealth.com/genetictests/familion.

For more information about Climb to Conquer, visit: http://www.sads.org/Climb/index.htm.

About PGxHealth

PGxHealth[TM] has extensive experience and capabilities in the development, clinical validation and delivery of genomic-based tests, in particular in the areas of efficacy and safety biomarkers for appropriate drug utilization. Through its own know-how and resources, work conducted with some of the world's most prestigious genomics thought leaders and institutions, and use of innovative technologies, PGxHealth is focused on reducing treatment costs and improving clinical outcomes in those disease states and therapeutic classes beset with expensive, inefficient or suboptimal treatment options. It has branded its genetic tests based on these proprietary genetic markers Therapeutic Diagnostics(TM).

About FAMILION

By detecting genetic mutations, FAMILION can be used to recognize cardiac channelopathies such as LQTS and Brugada Syndrome in individuals and their families and guide treatment to prevent the deadly cardiac events they can cause.

About Clinical Data, Inc.

Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, from targeted science to better healthcare. Its Cogenics division provides molecular biology and pharmacogenomics services to pharmaceutical and biotech companies and academics institutions in both research and regulated environments. Its PGxHealth division focuses on genetic test and biomarker development to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Vital Diagnostics division offers in vitro diagnostics solutions for the clinical laboratory. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists, and health plans worldwide.

Internet Website: www.clda.com

About the SADS Foundation

The SADS Foundation is committed to supporting families and individuals with genetically mediated cardiac arrhythmias through education, research, and advocacy. Its primary goals are:

1. General Awareness/Prevention: Proactively increase the general public's knowledge of the warning signs of heart rhythm abnormalities that can cause sudden death in the young.

2. Family Support: To provide information, resources, and support to assist patients and families to make informed medical decisions and to live with the challenges of these conditions.

3. Education-professionals: To facilitate early diagnosis and treatment of heart rhythm abnormalities by implementing strategies to ensure that healthcare providers have all available current and relevant information.

4. Advocacy: To encourage research, to advocate for nondiscriminatory treatment, and to support efforts that will improve the quality of life for patients with heart rhythm abnormalities.

Internet Website: http://www.sads.org/

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to statements regarding: our ability to successfully integrate the operations, business, technology and intellectual property obtained in our acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: whether our PGxPredict tests will gain wide acceptance in the market; the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety; our ability to achieve the expected synergies and operating efficiencies from all of our acquisitions; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for pharmacogenetic and biomarker products and services; general economic downturns; and other risks contained in our various SEC reports and filings, including but not limited to our Quarterly Report on Form 10-Q for the quarter ended December 31, 2006, and our subsequent Current Reports on Form 8-K filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.